David Cory, Eiger BioPharmaceuticals CEO (via MultiVu)
FDA rejects Eiger's emergency use request for repurposed Covid-19 treatment
Eiger BioPharmaceuticals is no longer planning to submit an emergency use application to the FDA.
The Palo Alto, CA-based biotech had hoped to repurpose its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
